Sumitomo Pharma Co., Ltd.
4506.T · JPX
3/31/2025 | 3/31/2024 | 3/31/2023 | 3/31/2022 | |
|---|---|---|---|---|
| Revenue | ¥398,832,000 | ¥314,558,000 | ¥555,544,000 | ¥560,035,000 |
| % Growth | 26.8% | -43.4% | -0.8% | – |
| Cost of Goods Sold | ¥153,437,000 | ¥126,577,000 | ¥178,919,000 | ¥157,127,000 |
| Gross Profit | ¥245,395,000 | ¥187,981,000 | ¥376,625,000 | ¥402,908,000 |
| % Margin | 61.5% | 59.8% | 67.8% | 71.9% |
| R&D Expenses | ¥49,865,000 | ¥112,637,000 | ¥131,858,000 | ¥94,903,000 |
| G&A Expenses | ¥180,605,000 | ¥429,538,000 | ¥279,355,000 | ¥179,559,000 |
| SG&A Expenses | ¥180,605,000 | ¥429,538,000 | ¥339,212,000 | ¥217,339,000 |
| Sales & Mktg Exp. | ¥0 | ¥0 | ¥59,857,000 | ¥37,780,000 |
| Other Operating Expenses | -¥13,879,000 | ¥0 | -¥139,327,000 | ¥30,432,000 |
| Operating Expenses | ¥216,591,000 | ¥542,175,000 | ¥331,743,000 | ¥342,674,000 |
| Operating Income | ¥28,804,000 | -¥354,194,000 | -¥76,979,000 | ¥60,234,000 |
| % Margin | 7.2% | -112.6% | -13.9% | 10.8% |
| Other Income/Exp. Net | -¥11,193,000 | ¥31,080,000 | ¥29,059,000 | ¥22,727,000 |
| Pre-Tax Income | ¥17,611,000 | -¥323,114,000 | -¥47,920,000 | ¥82,961,000 |
| Tax Expense | -¥6,024,000 | -¥8,185,000 | ¥48,794,000 | ¥42,361,000 |
| Net Income | ¥23,634,000 | -¥314,969,000 | -¥74,512,000 | ¥56,413,000 |
| % Margin | 5.9% | -100.1% | -13.4% | 10.1% |
| EPS | 59.49 | -792.79 | -187.55 | 141.99 |
| % Growth | 107.5% | -322.7% | -232.1% | – |
| EPS Diluted | 59.49 | -792.79 | -187.55 | 141.99 |
| Weighted Avg Shares Out | 397,290 | 397,292 | 397,292 | 397,293 |
| Weighted Avg Shares Out Dil | 397,290 | 397,292 | 397,292 | 397,293 |
| Supplemental Information | – | – | – | – |
| Interest Income | ¥2,307,000 | ¥36,022,000 | ¥32,218,000 | ¥25,777,000 |
| Interest Expense | ¥13,500,000 | ¥4,277,000 | ¥3,159,000 | ¥3,050,000 |
| Depreciation & Amortization | ¥25,562,000 | ¥37,765,000 | ¥41,263,000 | ¥38,348,000 |
| EBITDA | ¥56,673,000 | -¥281,072,000 | -¥3,498,000 | ¥124,359,000 |
| % Margin | 14.2% | -89.4% | -0.6% | 22.2% |